Abstract: A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound possessing prostaglandin skeleton as a representative, possesses promoting action on bone formation, so it is useful for prevention and/or treatment of diseases associated with decrease in bone mass (bone diseases such as primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss and bone necrosis, postoperative osteogenesis, alternative therapy for bone grafting).

Abstract: An intracellular calcium concentration increase inhibitor containing as the active ingredient (1) a boron compound represented by the formula (I).

Abstract: A pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient.

Abstract: An agent comprising the benzoic acid of formula (I) 1

Abstract: The treatment and/or prophylactic drugs of post-traumatic stress disorder (PTSD) containing compounds(EP1 agonists), which activate EP1 receptor that is subtype of prostaglandin E2 receptor, as an active ingredient. EP1 agonists such as (13E)-(11&agr;, 15S, 17S)-2, 5-ethano-6, 9-dioxo-11, 15-dihydro-17, 20-dimethylprosta-13-enoic acid, PGE1, or PGE2, etc. are useful for the treatment of post-traumatic stress disorder (PTSD).

Abstract: A pharmaceutical composition for the treatment and/or prevention of depression comprising a compound having an antagonistic activity for EP1 receptor which a prostaglandin E2 receptor subtype.

Abstract: An agent comprising the benzoic acid of formula (I) wherein A, B, R6, R7 are carbocyclic ring, heterocyclic ring, etc.; R1 is hydroxy etc.; R2, R3, R4 are alkyl etc.; R5, D, E are alkylene, etc.; G is oxygen etc., as active ingredient. The compound of formula (I) is considered to be useful for the treatment and/or prophylaxis of bone diseases, cancer, systemic granuloma, immunological diseases, allergy, atopy, asthma, gumboil, gingivitis, periodontitis, neurocyte death, Alzheimer's diseases, lungs injury, pulmopathy, acute hepatitis, nephritis, myocardial ischemia, Kawasaki disease, ambustion, ulcerative colitis, Crohn's disease, multiple organ failure, sleeping disorder, platelet aggregation, etc.

Abstract: A method of producing a silicon carbide single crystal in which a sublimation raw material 40 is accommodated at the side of vessel body 12 in a graphite crucible 10, placing a seed crystal of a silicon carbide single crystal at the side of cover body 11 of the graphite crucible 10, the sublimation raw material 40 is sublimated by a first induction heating coil 21 placed at the side of sublimation raw material 40, a re-crystallization atmosphere is form by a second induction heating coil 20 placed at the side of cover body 11 so that the sublimation raw material 40 sublimated by the first induction heating coil 21 is re-crystallizable only in the vicinity of the seed crystal of a silicon carbide single crystal, and the sublimation raw material 40 is re-crystallized on the seed crystal of a silicon carbide single crystal, and a silicon carbide single crystal 60 is grown while keeping the whole surface of its growth surface in convex shape through the all growth processes.

Abstract: An agent comprising the benzoic acid of formula (I) 1

Abstract: A silicon carbide single crystal which can be suitably used as a semi-insulating or insulating single crystal substrate and the like, and a method of efficiently producing the same, are provided.

Abstract: In order to provide an RF coil for effective imaging from a vertex to an upper T spine, a coil surrounding a forehead portion of an imaging object, a coil surrounding a nose portion over the protuberance of the nose, a coil surrounding the neck, and a coil holding the upper T spine, are integrally molded to construct a coil assembly which can be separated into front and rear parts.

Abstract: The present invention provides 11,15-O-dialkyl prostaglandin E derivatives of formula (I) (wherein all symbols are as described in Specification), or non-toxic salts thereof or cyclodextrin clathrates thereof, processes for the preparation thereof and pharmaceutical compositions containing them as active ingredient. A compound of formula (I) binds strongly and acts on EP3 receptor which is a subtype of PGE2 receptor and therefore is useful for prevention and/or treatment of liver diseases, kidney diseases, pancreatitis, myocardial infarction etc.

Abstract: An electro-rheological fluid made from an oil medium and fine particulates by mixing, is highly reliable and in which dielectric breakdown, such as generation of electrical discharge, is very low even when a high voltage is applied. A method of manufacturing the electro-rheological fluid and a method of storing the fluid are also provided. The electro-rheolological fluid includes fine particulates dispersed in an oil medium having an electric insulation property, and has a dielectric breakdown strength of 4 kV/mm or more. When the electro-rheological fluid is placed under a reduced pressure of 10 Pa, foaming does not occur. Alternatively, the electro-reheoleological fluid can contain 20% by volume or more of a gas contained in the oil medium that has a dielectric breakdown strength of 4 kV/mm or more.

Abstract: A benzenesulfonamide compound of the formula (I) (R1 is hydroxy, C1˜4 alkoxy, NR6R7 (each R6 and R7 is, independently, H or C1˜4 alkyl.); R2 is H, C1˜4 alkyl; R3, R4 are C1˜4 alkyl, halogen trifluoromethyl; R5 is H, C1˜4 alkyl, halogen, trifluoromethyl; Y is cis-vinylene, trans-vinylene; and the symbol (i) is single bond, double bond.), non-toxic salt thereof or cyclodextrin clathrate thereof and an antagonist of EP1 receptor which is a prostaglandin E2 receptor subtype comprising it as an active ingredient. The present invention compounds of the of the formula (I) can bind strongly to EP1 receptor which is a prostaglandin E2 receptor subtype and scarcely bind to the other receptor subtypes. Therefore, they are considered to be useful as antipyretic agents, as analgesics or as treating agent for pollakiuria having little side effect.

Abstract: A naphthyloxyacetic acid derivative of the formula (I) ##STR1## wherein R.sup.1 is H, alkyl, alkylene-(--COOR.sup.10, --OH, --CONR.sup.4 R.sup.5, --CONR.sup.6 -alkylene-OH, --NR.sup.4 R.sup.5, -cyano or -tetrazolyl); A is single bond, alkylene, alkenylene, --S-alkylene, --O-alkylene; B is NR.sup.3 CO, CONR.sup.3 ; R.sup.2 is (1) alkyl (2) alkenyl, (3) alkyl or alkenyl substituted by 1-3 of phenyl, cycloalkyl, naphthyl and heterocyclic ring containing nitrogen atom (the said ring may be substituted by 1-3 of alkyl, alkoxy and halogen etc.), (4) NR.sup.7 R.sup.8 or (5) alkylene-NR.sup.7 R.sup.8 ; non-toxic salt thereof, non-toxic acid addition salt thereof and hydrate thereof can bind the PGE.sub.2 receptor and exhibits the activity to antagonize or agonize for PGE.sub.2., therefore, they are useful as PGE.sub.2 antagonist or PGE.sub.2 agonist.

Abstract: An electrorheological fluid is constituted by using a dispersed phase of a carbonaceous powder having an oxygen content above 10% by weight but not more than 20% by weight and having an average particle diameter of 0.01-100 .mu.m, obtained by:heat-polymerizing a condensed polycyclic aromatic compound containing a main component of naphthalene by using HF/BF.sub.3 as a catalyst to obtain a 100% meso-phase pitch having a softening point within a range of 150.degree.-400.degree. C.;heat-treating and making the pitch infusible in an oxidizing atmosphere at a temperature not more than a fusing temperature of the pitch and not less than 50.degree. C. but not more than 400.degree. C. to allow the pitch to have an oxygen content of 12-25% by weight; and thenheat-treating and carbonizing the pitch in an inert gas atmosphere at a temperature not less than 300.degree. C. but not more than 700.degree. C.

Abstract: A naphthyloxyacetic acid derivative of the formula (I) ##STR1## wherein R.sup.1 is H, alkyl, alkylene-(--COOR.sup.10, --OH, --CONR.sup.4 R.sup.5, --CONR.sup.6 -alkylene-OH, --NR.sup.4 R.sup.5, -cyano or -tetrazolyl); A is single bond, alkylene, alkenylene, --S-alkylene, --O-alkylene; B is NR.sup.3 CO, CONR.sup.3 ; R.sup.2 is (1) alkyl (2) alkenyl, (3) alkyl or alkenyl substituted by 1-3 of phenyl, cycloalkyl, naphthyl and heterocyclic ring containing nitrogen atom (the said ring may be substituted by 1-3 of alkyl, alkoxy and halogen etc.), (4) NR.sup.7 R.sup.8 or (5) alkylene-NR.sup.7 R.sup.8 ; non-toxic salt thereof, non-toxic acid addition salt thereof and hydrate thereof can bind the PGE.sub.2 receptor and exhibits the activity to antagonize or agonize for PGE.sub.2, therefore, they are useful as PGE.sub.2 antagonist or PGE.sub.2 agonist.

Abstract: (1) Naphthyloxyaetic acid represented by the compound of the formula (I): ##STR1## and non-toxic salts thereof, (2) process for the preparation of the compounds represented by the compound of the formula (I) described hereinbefore,(3) PGE.sub.2 antagonist or agonist containing the compound represented by the compound of the formula (I) as the active ingredient.The compounds represented by the compounds of the formula (I) can be adapted to medicines which possess an inhibitory effect of uterine contraction, an analgesic action, an inhibitory effect of digestive peristalsis, a sleep-inducing effect as PGE.sub.2 antagonists, and an uterine contractile activity, a promoting effect of digestive peristalsis, a suppressive effect of gastric acid secretion, hypotensive activity as PGE.sub.2 agonists. The compounds bind to PGE.sub.2 receptor and have an activity of antagonist or agonist against the action thereof.

Abstract: (1) Naphthyloxyaetic acid represented by the compound of the formula (I): ##STR1## and non-toxic salts thereof, (2) process for the preparation of the compounds represented by the compound of the formula (I) described hereinbefore,(3) PGE.sub.2 antagonist or agonist containing the compound represented by the compound of the formula (I) as the active ingredient.The compounds represented by the compounds of the formula (I) can be adapted to medicines which possess an inhibitory effect of uterine contraction, an analgesic action, an inhibitory effect of digestive peristalsis, a sleep-inducing effect as PGE.sub.2 antagonists, and an uterine contractile activity, a promoting effect of digestive peristalsis, a suppressive effect of gastric acid secretion, hypotensive activity as PGE.sub.2 agonists. The compounds bind to PGE.sub.2 receptor and have an activity of antagonist or agonist against the action thereof.

Abstract: The present invention relates to an electrorheological semisolid capable of changing the rheological characteristics by an application of voltage. The semisolid is composed of 20-70 weight. Parts of carbonaceous particulates having an average particle size of 0.1-500 .mu.m and a carbon/hydrogen atomic ratio (C/H ratio) of 1.2-5 which are dispersed in 80-30 weight % of a dispersion medium comprising a partially crosslinked electric insulating polymer having a penetration of 40-475 at 25.degree. C., or into 80-30 weight % of a dispersion medium selected from an electric insulating oil having a viscosity of 5000 to 10.sup.9 centistokes at 25.degree. C. and an electric insulating polymer having a viscosity of 5000 to 10.sup.9 centistokes at 25.degree. C.